FAMOTIDINE- famotidine tablet, film coated

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

FAMOTIDINE (UNII: 5QZO15J2Z8) (FAMOTIDINE - UNII:5QZO15J2Z8)

Available from:

Camber Pharmaceuticals, Inc.

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H 2 ) receptor antagonists. Risk Summary Available data with H 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse mater

Product summary:

Famotidine Tablets USP, 20 mg, are light yellow, round, biconvex, film-coated tablets debossed with “T” on one side and “11” on the other side. They are supplied as follows: Bottles of 100                                     NDC 31722-017-01 Bottles of 1000                                   NDC 31722-017-10 Famotidine Tablets USP, 40 mg, are white, round, biconvex, film-coated tablets debossed with “T” on one side and “12” on the other side. They are supplied as follows: Bottles of 100                                     NDC 31722-018-01 Bottles of 500                                     NDC 31722-018-05 Bottles of 1000                                   NDC 31722-018-10 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a USP tight, light-resistant container.

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

FAMOTIDINE - FAMOTIDINE TABLET, FILM COATED
CAMBER PHARMACEUTICALS, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
FAMOTIDINE TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
FAMOTIDINE TABLETS.
FAMOTIDINE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1986
INDICATIONS AND USAGE
Famotidine tablets are a histamine-2 (H
) receptor antagonist indicated ( 1):
In adult and pediatric patients 40 kg and greater for the treatment
of:
• active duodenal ulcer (DU).
• active gastric ulcer.
• symptomatic nonerosive gastroesophageal reflux disease (GERD).
• erosive esophagitis due to GERD, diagnosed by biopsy.
In adults for the:
• treatment of pathological hypersecretory conditions (e.g.,
Zollinger-Ellison syndrome, multiple endocrine
neoplasias).
• reduction of the risk of DU recurrence.
DOSAGE AND ADMINISTRATION
Indication
Recommended Dosage ( 2.1)
_Adult and Pediatric Patients_
_40 kg and greater_
Active DU
40 mg once daily; or 20 mg twice daily
Active Gastric Ulcer
40 mg once daily
GERD
20 mg twice daily
Erosive Esophagitis
20 mg twice daily; or 40 mg twice daily
_Adults_
Pathological Hypersecretory
Conditions
20 mg every 6 hours; adjust to patient needs; maximum 160 mg every
6 hours
Risk Reduction of DU
Recurrence
20 mg once daily
• See full prescribing information for complete dosing information,
including dosing in renal impairment,
and recommended treatment duration. ( 2.1, 2.2)
Administration ( 2.3):
• Take once daily before bedtime or twice daily in the morning and
before bedtime with or without food.
DOSAGE FORMS AND STRENGTHS
Tablets: 20 mg, 40 mg ( 3)
CONTRAINDICATIONS
History of serious hypersensitivity reactions (e.g., anaphylaxis) to
famotidine or other H
receptor
antagonists. ( 4)
WARNINGS AND PRECAUTIONS
• Central Nervous System (CNS) Adverse Reactions: Elderly patients
and patients with renal impairment
at increased risk; reduce the dosage. ( 2.2, 5.1, 8.5, 8.6)
• GI Malignancy: Absence of GI sympt